Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Mallinckrodt
Dow
Cipla
Healthtrust
Merck
Federal Trade Commission
Johnson and Johnson
Julphar

Generated: August 21, 2018

DrugPatentWatch Database Preview

BAYER Company Profile

« Back to Dashboard

Summary for BAYER
International Patents:1548
US Patents:50
Tradenames:110
Ingredients:75
NDAs:127
Patent Litigation for BAYER: See patent lawsuits for BAYER

Drugs and US Patents for BAYER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare BILIVIST ipodate sodium CAPSULE;ORAL 087768-001 Aug 11, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Pharms AZLIN azlocillin sodium INJECTABLE;INJECTION 050562-002 Sep 3, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Pharms AZLIN azlocillin sodium INJECTABLE;INJECTION 062388-003 Sep 8, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare FINACEA azelaic acid AEROSOL, FOAM;TOPICAL 207071-001 Jul 29, 2015 RX Yes Yes 9,211,259 ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Pharms LITHANE lithium carbonate TABLET;ORAL 018833-001 Jul 18, 1985 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-001 Aug 19, 2003 RX Yes No 6,362,178 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Bayer Healthcare ALIQOPA copanlisib dihydrochloride POWDER;INTRAVENOUS 209936-001 Sep 14, 2017 RX Yes Yes 9,636,344 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for BAYER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare CLIMARA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020375-004 Mar 5, 1999 5,223,261 ➤ Try a Free Trial
Bayer Hlthcare GADAVIST gadobutrol SOLUTION;INTRAVENOUS 201277-001 Mar 14, 2011 5,980,864 ➤ Try a Free Trial
Bayer Healthcare Llc ZEGERID OTC omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 022283-001 Jun 17, 2013 7,399,772 ➤ Try a Free Trial
Bayer Hlthcare MYCELEX clotrimazole SOLUTION;TOPICAL 018181-001 Approved Prior to Jan 1, 1982 3,705,172 ➤ Try a Free Trial
Bayer Hlthcare AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER moxifloxacin hydrochloride SOLUTION;IV (INFUSION) 021277-001 Nov 30, 2001 5,607,942 ➤ Try a Free Trial
Bayer Hlthcare MYCELEX clotrimazole TROCHE/LOZENGE;ORAL 018713-001 Jun 17, 1983 3,839,573 ➤ Try a Free Trial
Bayer Healthcare Llc CLARITIN loratadine SYRUP;ORAL 020641-002 Nov 27, 2002 4,863,931*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for BAYER drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2009-09-04
➤ Subscribe Capsules 20 mg/1100 mg ➤ Subscribe 2010-04-20
➤ Subscribe Tablets 200 mg ➤ Subscribe 2014-02-28
➤ Subscribe Topical Foam 15% ➤ Subscribe 2017-09-14
➤ Subscribe Tablets 3 mg/0.03 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-09-28
➤ Subscribe Oral Suspension 250 mg/5 mL and 500 mg/ 5 mL ➤ Subscribe 2009-10-16
➤ Subscribe Tablets 3 mg/0.02 mg ➤ Subscribe 2006-09-29
➤ Subscribe Injection 1.6 mg/mL ➤ Subscribe 2014-02-07
➤ Subscribe Tablets 0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg ➤ Subscribe 2017-10-10
➤ Subscribe Tablets 0.25 mg/0.5 mg ➤ Subscribe 2015-01-08
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-11-13
➤ Subscribe Tablets 5 mg ad 10 mg ➤ Subscribe 2009-07-10
➤ Subscribe Tablets 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg ➤ Subscribe 2010-10-22
➤ Subscribe Gel 15% ➤ Subscribe 2012-07-27
➤ Subscribe Tablets 25 mg, 50 mg and 100 mg ➤ Subscribe 2005-03-22
➤ Subscribe Transdermal System 0.05 mg/day and 0.1 mg/day ➤ Subscribe 2005-09-12
➤ Subscribe Tablets 40 mg ➤ Subscribe 2016-09-27
➤ Subscribe Gel 0.05% ➤ Subscribe 2010-12-01
➤ Subscribe Tablets 3 mg/0.03 mg ➤ Subscribe 2005-01-07
➤ Subscribe Orally Disintegrating Tablets 10 mg ➤ Subscribe 2011-12-22
➤ Subscribe Tablets 0.5 mg/1 mg ➤ Subscribe 2007-12-26
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2011-11-21
➤ Subscribe Tablets 20 mg ➤ Subscribe 2009-03-05
Premature patent expirations for BAYER

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Try a Free Trial ➤ Try a Free Trial

Non-Orange Book US Patents for BAYER

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,704,999 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors ➤ Try a Free Trial
8,298,515 Vitamin formulation ➤ Try a Free Trial
6,890,922 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors ➤ Try a Free Trial
7,122,540 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors ➤ Try a Free Trial
8,114,385 Oleaginous pharmaceutical and cosmetic foam ➤ Try a Free Trial
6,399,043 1,4,7,10-Tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them ➤ Try a Free Trial
7,569,557 Compositions of estrogen-cyclodextrin complexes ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for BAYER Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009 00017 Denmark ➤ Try a Free Trial PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
2/2005 Austria ➤ Try a Free Trial PRODUCT NAME: INSULIN GLULISINE
2014000114 Germany ➤ Try a Free Trial PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918
00111 Netherlands ➤ Try a Free Trial PRODUCT NAME: MOXIFLOXACINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER MOXIFLOXACINEHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 28118 RVG 28119 20021017; FIRST REGISTRATION: DE 45263.00.00 19990621
0596 Netherlands ➤ Try a Free Trial PRODUCT NAME: INSULINE DEGLUDEC; NATIONAL REGISTRATION NO/DATE: EU/1/12/807/004 20130123; FIRST REGISTRATION: EU EU/1/12/807/001 20130123
2107069/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: INSULIN DEGLUDEC; REGISTRATION NO/DATE: SWISSMEDIC 62563 12.03.2013
280 Luxembourg ➤ Try a Free Trial 91280, EXPIRES: 20210720
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Medtronic
Chubb
Fuji
Federal Trade Commission
Cipla
Colorcon
Julphar
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.